Quinapril/Hydrochlorothiazide Tablet Shortage: Current FDA Status and Availability Updates
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has listed Quinapril/Hydrochlorothiazide tablets as being in a current shortage status, though several presentations remain available from manufacturers.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Quinapril.
What's in Shortage
Quinapril/Hydrochlorothiazide tablets, a medication used in the Cardiovascular therapeutic category, are currently listed in a shortage status by the FDA. This affects the generic version as well as the brand name QUINAPRIL AND HYDROCHLOROTHIAZIDE.
- Current Status: Current Shortage
- Dosage Form: Tablet
- Initial Posting Date: 01/19/2023
- Last Updated: 02/02/2026
Which Manufacturers Are Affected
According to the latest data, the following manufacturer is supplying the medication with the following availability status:
- Chartwell Molecular Holdings LLC
- Status: Available
- Presentations:
- Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)
- Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)
- Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)
- Contact Information: 845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com
Why There's a Shortage
No specific reason for the shortage was provided in the source data.
What Patients Should Do
If you are currently prescribed Quinapril/Hydrochlorothiazide, please consider the following steps:
- Consult Your Pharmacist: Check with your local pharmacy regarding their current stock levels for your specific dosage.
- Contact Your Healthcare Provider: Discuss your treatment plan and ask about potential alternatives if your specific dosage becomes difficult to find.
- Contact the Manufacturer: You may reach out to Chartwell Molecular Holdings LLC at the contact information provided above for updates on supply.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider or pharmacist regarding their medications and treatment options.
Source
Information provided by the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.